Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
3 hedge funds and large institutions have $360K invested in Global X China Biotech Innovation ETF in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
29% more capital invested
Capital invested by funds: $278K → $360K (+$82K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$35.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $190K | +$201K | +16,484 | New |
|
|
2
Jane Street
New York
| $167K | -$35.5K | -2,907 | -17% |
|
|
BBPWM
3
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $3K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$25K | -1,749 | Closed |
|
CHB Hedge Fund Activity: Q1 2022 in Review
3 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q1 2022, worth a combined $360K — up 29% from $278K a quarter earlier.
Fund positioning in CHB was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $201K. The largest seller was Jane Street, cutting an estimated $35.5K.
- 3 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $360K of Global X China Biotech Innovation ETF stock for Q1 2022, up 29% quarter-over-quarter.
- 1 fund opened new Global X China Biotech Innovation ETF positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Global X China Biotech Innovation ETF buyer in Q1 2022 was Susquehanna International Group, an estimated $201K added.
- The largest Global X China Biotech Innovation ETF seller in Q1 2022 was Jane Street, an estimated $35.5K sold.
Based on aggregated 13F filings for Q1 2022.